Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3949MR)

This product GTTS-WQ3949MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&FCRL5 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001195388.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 83416
UniProt ID P07766; Q96RD9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3949MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1764MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ11310MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-522
GTTS-WQ10590MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ8108MR IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HGS-ETR2
GTTS-WQ5010MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ6069MR IVTScrip™ mRNA-Anti-CCL2, CNTO 888(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 888
GTTS-WQ15223MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ2934MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG888
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW